Title:A Novel Recombinant Multi-Epitope Vaccine Could Induce Specific Cytotoxic T Lymphocyte Response In Vitro and In Vivo
Volume: 24
Issue: 6
Author(s): Yahong Wu, Wenjie Zhai, Meng Sun, Zhe Zou, Xiuman Zhou, Guodong Li, Zhongyi Yan, Yuanming Qi*Yanfeng Gao*
Affiliation:
- School of Life Sciences, Zhengzhou University, 100 Kexue Road, Zhengzhou 450001,China
- School of Life Sciences, Zhengzhou University, 100 Kexue Road, Zhengzhou 450001,China
Keywords:
Cytotoxic T lymphocytes, vaccine, cancer immunotherapy, HLA-A2, epitope, YL66.
Abstract: Background: Malignant tumor is still one of the important diseases worldwide, cytotoxic
CD8+ T lymphocytes (CTLs) play an important role in killing tumor cells.
Objective: To enhance the immune response of our previously identified HLA-A2-restricted CTL
epitopes, we designed a multiepitope YL66.
Method: The fusion protein GST-YL66 and DNA vaccine pcDNA3.1(+)-YL66 were used to induce
CTLs from human peripheral blood mononuclear cells (PBMCs) of HLA-A*02
+ healthy donors and
and in HLA-A2.1/K
b transgenic(Tg) mice. and the activity of induced CTLs were tested by IFN-γ
relesde ELISPOT assay and LDH cytotoxicity assay.
Results: GST-YL66 induced CTL could lysis tumor cells and release IFN-γ both
in vitro and
in vivo,
and pcDNA3.1(+)-YL66 could also induce significant CTL response in vivo.
Conclusion: The designed fusion multiepitope YL66 could be used as a vaccine against patients with
tumors expressing COX-2 and/or MAGE-4.
